Functional and Anatomical Outcomes Following Intravitreal Bevacizumab in Treatment-Naïve Centre-Involving Diabetic Macular Edema: A 3-Month Prospective Evaluation
Open AccessAuthors
-
Sanjay Kumar Mishra
Nims University Rajasthan, Jaipur
https://orcid.org/0009-0003-0636-7727
-
Tejinder Singh Ahluwalia
Nims University Rajasthan, Jaipur, Rajasthan INDIA
https://orcid.org/0009-0002-3527-061X
-
Rajpal Vohra
Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA
https://orcid.org/0000-0003-3308-969X
-
Rohan Chawla
Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA
https://orcid.org/0000-0002-6791-4435
Keywords:
Diabetic Macular Edema, Bevacizumab, Central Macular Thickness, Anti-VEGF, Retinal Sensitivity, Microperimetry, OCT, Intravitreal InjectionAbstract
Introduction: Diabetic macular edema (DME) remains a major cause of vision impairment worldwide. Intravitreal bevacizumab, though used off-label, is an established therapy for centre-involved DME (CI-DME). This study evaluated how effectively microperimetry complements standard measures—best-corrected visual acuity (BCVA) and central macular thickness (CMT)—in assessing treatment outcomes.
Methods: In this prospective observational study, 52 eyes with treatment-naïve CI-DME received three monthly bevacizumab injections. BCVA, CMT (via OCT), and mean retinal sensitivity (by microperimetry) were recorded at baseline, one month, and three months. Statistical analyses included the Wilcoxon signed-rank test for repeated measures and Spearman’s rank correlation for structure–function relationships.
Results: After three months, mean BCVA improved from 0.50 ± 0.095 to 0.67 ± 0.088 (p < 0.001), while CMT decreased from 401.9 ± 87.6 µm to 329.5 ± 23.2 µm (p < 0.001). Mean retinal sensitivity rose from 14.96 ± 1.01 dB to 16.50 ± 1.39 dB (p < 0.001). Improvement in BCVA correlated positively with both CMT reduction (ρ = 0.340, p = 0.014) and sensitivity gain (ρ = 0.412, p = 0.004), while CMT reduction correlated inversely with sensitivity improvement (ρ = –0.367, p = 0.009).
Conclusion: Three consecutive bevacizumab injections resulted in significant anatomical and functional recovery in eyes with CI-DME. The consistent correlations between macular structure and function underscore the value of microperimetry as a sensitive, complementary tool for evaluating therapeutic response beyond standard acuity and OCT metrics.
Downloads
Metrics
References
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine, 355(14), 1432–1444. https://doi.org/ DOI: https://doi.org/10.1056/NEJMoa062655
1056/NEJMoa062655
Diabetic Retinopathy Clinical Research Network, Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M., Browning, D. J., Elman, M. J., Ferris, F. L., Friedman, S. M., Melia, M., Pieramici, D. J., Sun, J. K., & Beck, R. W. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England Journal of Medicine, 372(13), 1193–1203. https://doi.org/
1056/NEJMoa1414264
Ferrara, N., & Adamis, A. P. (2016). Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 15(6), 385–403. https://doi.org/10.1038/nrd.2015.17 DOI: https://doi.org/10.1038/nrd.2015.17
Ihsan, G., Kwartika, A., Widyanatha, M. I., Virgana, R., Iskandar, E., & Kartasasmita, A. S. (2024). Early response of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema management: Microperimetry and optical coherence tomography findings—A pilot study at the National Eye Center of a third-world country. BMC Ophthalmology, 24(1), 551. https://doi.org/10.1186/s12886-024-03744-8 DOI: https://doi.org/10.1186/s12886-024-03744-8
Laishram, M., Srikanth, K., Rajalakshmi, A., Nagarajan, S., & Ezhumalai, G. (2017). Microperimetry – A new tool for assessing retinal sensitivity in macular diseases. Journal of Clinical and Diagnostic Research (JCDR), 11(7), NC08–NC11. https://doi.org/10.7860/ DOI: https://doi.org/10.7860/JCDR/2017/25799.10213
JCDR/2017/25799.10213 DOI: https://doi.org/10.5465/AMBPP.2017.10213abstract
Magliano, D. J., Boyko, E. J., & International Diabetes Federation 10th edition Scientific Committee. (2021). Global picture. In IDF Diabetes Atlas (10th ed.). International Diabetes Federation. https://www.ncbi.nlm.nih.gov/boo
ks/NBK581940/
Midena, E., Frizziero, L., Torresin, T., & Pilotto, E. (2024). Microperimetry as a biomarker of macular function in diabetic macular edema: Correlation with OCT and treatment outcomes. Frontiers in Ophthalmology, 3, Article 1197448. https://doi.org/10.3389/fopht.2024.1197448
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., Weichselberger, A., & RESTORE Study Group. (2011). The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118(4), 615–625. https://doi.or DOI: https://doi.org/10.1016/j.ophtha.2011.01.031
g/10.1016/j.ophtha.2011.01.031
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., Rubio, R. G., Ehrlich, J. S., & RISE and RIDE Research Group. (2012). Ranibizumab for diabetic macular edema: Results from two phase III randomized trials—RISE and RIDE. Ophthalmology, 119(4), 789–801. https://doi.or DOI: https://doi.org/10.1016/j.ophtha.2011.12.039
g/10.1016/j.ophtha.2011.12.039
Pereira, F., Godoy, B. R., Maia, M., & Regatieri, C. V. (2019). Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: A pilot study. International Journal of Retina and Vitreous, 5, 24. https://doi.org/10.1186/s40942-019-0176-9 DOI: https://doi.org/10.1186/s40942-019-0176-9
Sugimoto, M., Tsujikawa, A., Miyamoto, K., Hata, Y., & Yoshimura, N. (2016). Importance of central retinal sensitivity for prediction of visual outcome after anti-VEGF therapy for diabetic macular edema. PLOS ONE, 11(7), e0159771. https://doi.org/10.1371/journal.pone.0159771 DOI: https://doi.org/10.1371/journal.pone.0149246
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119. https://doi.org/ DOI: https://doi.org/10.1016/j.diabres.2021.109119
1016/j.diabres.2021.109119
Udaondo, P., Parravano, M., Vujosevic, S., Zur, D., & Chakravarthy, U. (2022). Update on current and future management for diabetic maculopathy. Ophthalmology and Therapy, 11(2), 277–298. https://doi.org/10.1007/s40123-022-00460-8 DOI: https://doi.org/10.1007/s40123-022-00460-8
Vujosevic, S., Bottega, E., Casciano, M., Pilotto, E., Convento, E., & Midena, E. (2010). Microperimetry and fundus autofluorescence in diabetic macular edema: Subthreshold micropulse diode laser versus modified ETDRS laser photocoagulation. Retina (Philadelphia, Pa.), 30(6), 908–916. https://doi.org/10.1097/I DOI: https://doi.org/10.1097/IAE.0b013e3181c96986
AE.0b013e3181c96986
Vujosevic, S., Midena, E., Pilotto, E., Radin, P. P., Chiesa, L., & Cavarzeran, F. (2006). Diabetic macular edema: Correlation between microperimetry and optical coherence tomography findings. Investigative Ophthalmology & Visual Science, 47(7), 3044–3051. https://doi.org/10.1167/iovs.05-1141 DOI: https://doi.org/10.1167/iovs.05-1141
Wang, P., Xu, Y., Chen, Z., & Zhang, X. (2022). Relationship between macular thickness and visual function in diabetic macular edema: A meta-analysis. Ophthalmology and Therapy, 11(4), 1567–1582. https://doi.org/10.1007/s401
-022-00525-8
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., Melia, M., Beck, R. W., & Diabetic Retinopathy Clinical Research Network. (2016). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomised clinical trial. Ophthalmology, 123(6), 1351–1359. https://doi.org/10.1016/j.ophtha.2016.02.022 DOI: https://doi.org/10.1016/j.ophtha.2016.02.022
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016). Diabetic retinopathy. Nature Reviews Disease Primers, 2, 16012. https://doi.org/10.1038/nrdp.2016.12 DOI: https://doi.org/10.1038/nrdp.2016.12
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S. J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., & Wong, T. Y. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35(3), 556–564. https://doi.org/10.2337/dc11-1909 DOI: https://doi.org/10.2337/dc11-1909
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sanjay Kumar Mishra, Tejinder Singh Ahluwalia, Rajpal Vohra, Rohan Chawla
This work is licensed under a Creative Commons Attribution 4.0 International License.
Citations
